These macros compute nonparametric survival curve estimates from interval-censored data. Confidence intervals for survival curves and log-rank tests comparing survival curves from several groups are also provided.
NOTE: Beginning with SAS/STAT 13.1 in SAS 9.4 TS1M1, the functionality of these macros has been updated and added to the ICLIFETEST procedure. For details, see the ICLIFETEST documentation.
PURPOSE:
These macros compute nonparametric maximum likelihood estimates (NPMLEs) of survival curves from interval-censored data. Confidence intervals for survival curves and log-rank tests comparing survival curves from several groups are also provided.
The %CumIncid macro for estimating and plotting cumulative incidence functions with competing risks is discussed.
This version of the CUMINCID macro applies only to SAS 9.1 which is available on the Downloads tab. For SAS 9.2 and later, refer to the Autocall macro library.
The CUMINCID macro computes the crude cumulative-incidence function estimates for homogeneous (no covariates) survival data whose endpoints are subjected to competing risks: see Kalbfleish and Prentice(1980). Standard errors and pointwise confidence limits are also computed. The estimated crude cumulative-incidence curve is displayed as a step function using ODS Graphics.
P. Silcocks. Journal of epidemiology and community health, 63 (10):
856-61(October 2009)5278<m:linebreak></m:linebreak>JID: 7909766; aheadofprint;<m:linebreak></m:linebreak>Anàlisi de supervivència.
S. Messinger, and S. Murray. Statistics in medicine, 24 (2):
301-18(January 2005)4149<m:linebreak></m:linebreak>PUBM: Print; JID: 8215016; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
D. Easton, J. Peto, and A. Babiker. Statistics in medicine, 10 (7):
1025-35(July 1991)4288<m:linebreak></m:linebreak>LR: 20061115; PUBM: Print; JID: 8215016; 0 (Contraceptives, Oral); CIN: Stat Med. 2004 Jan 15;23(1):93-104. PMID: 14695642; ppublish;<m:linebreak></m:linebreak>Mesures d'associació.
T. Lash, and S. Cole. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (23):
e55-6(August 2009)5436<m:linebreak></m:linebreak>JID: 8309333; 2009/07/13 aheadofprint; ppublish;<m:linebreak></m:linebreak>Mesures d'associació; Immortal time bias.
L. Chen, M. Yen, H. Wu, C. Liao, D. Liou, H. Kuo, and T. Chen. Journal of evaluation in clinical practice, 11 (2):
181-93(April 2005)3816<m:linebreak></m:linebreak>Anàlisi de supervivència; SAS.
G. Guyatt, R. Jaeschke, N. Heddle, D. Cook, H. Shannon, and S. Walter. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 152 (1):
27-32(January 1995)Anàlisi de dades; Introductori.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.